WASHINGTON, Jan. 13, 2026 — NGP VAN, the leading technology provider for Democratic and progressive campaigns and organizations, today announced the creation of its first-ever API and Data Products Team, alongside a seven-figure investment to modernize and expand the NGP VAN’s APIs. This new team will focus exclusively on strengthening the infrastructure that powers integrations across the progressive technology ecosystem.

This team – comprised entirely of union roles – will be dedicated to expanding API capabilities and delivering new data products in direct response to feedback from customers and integration partners, who increasingly rely on NGP VAN’s APIs as foundational scaffolding for building powerful tools and workflows.

“Our customers and partners have been clear: NGP VAN’s APIs are mission critical to modern organizing,” said Chelsea Peterson Thompson, General Manager of NGP VAN. “This investment reflects our responsibility to the ecosystem: focused teams, faster shipping, and an API engineered to scale with the future of campaigns and advocacy.” 

These new investments underscore the organization’s expanding role not only in supporting campaigns, parties, PACs, and progressive organizations directly, but also the wide range of third-party tools they rely on, including mobile messaging, digital advertising, analytics, and insights platforms.

The new API and Data Products Team also builds directly on NGP VAN’s Partner Program, by investing in dedicated API development, NGP VAN aims to deepen collaboration with partners and deliver world-class, reliable integrations that help Democratic and progressive campaigns move faster and smarter.

The announcement follows investments made in 2024 to expand API rate limits for all customers and vendors, enabling faster data synchronization while maintaining platform integrity.

Most recently, NGP VAN shipped several API enhancements to its Membership endpoints, including the ability to:

• Expose Membership Type via the Bulk Import method
• Support Member Type and Affiliates Custom Fields through Bulk Import
• Rename Custom Field values via a PUT method
• Expose the Apply Contributions mapping type

These updates reflect the company’s ongoing commitment to making its APIs more flexible, powerful, and responsive to real-world cases.

NGP VAN will be hiring three software engineers to form the core of the API and Data Products Team. As with all NGP VAN roles, those with experience building and scaling APIs are encouraged to apply at ngpvan.com/careers/. This team will be supported by continued investment in third-party platform modernization partners, as well as NGP VAN’s broader engineering organization, which has recently completed several API-focused initiatives. NGP VAN is a unionized employer.

About NGP VAN
NGP VAN is the winningest technology platform in the history of democratic and progressive causes, working tirelessly to innovate and advance the technology our clients rely on to bolster our democracy. We help power the trailblazers, campaigners, and advocates fighting up and down the ticket for equality, racial justice, reproductive freedom, democracy, climate reform, and more— including the national Democratic committees and progressive organizations, thousands of Democratic campaigns, hundreds of labor unions, advocacy organizations, progressive and non-partisan PACs, and other organizations.

Press Contact:
Simone Hassan-Bey
NGP VAN
[email protected]

SOURCE NGP VAN

LONDON, Jan. 13, 2026 — Dirk-Jan Vorgers and Ekaterina Kupriyanova, who formerly led the European office of Harvey & Company, have launched Aquisor, a European M&A buy-side advisory firm, focused on partnering with private equity firms to accelerate portfolio growth through platform and add-on acquisitions. Aquisor is backed by an experienced group of entrepreneurs and private equity professionals who have prior experience in the field.

Aquisor offers a fully dedicated service of pre-deal market mapping and buy-side deal origination, combining research-led target identification with direct outreach and structured project management to help clients generate more acquisition opportunities and better deals. Built on deep M&A and private equity experience, Aquisor leverages tech-enabled research and localised outreach in native languages with a disciplined workflow, designed to progress opportunities from initial engagement to closing of the deal.

Ekaterina Kupriyanova, COO at Aquisor, said: “Great M&A sourcing is, above all, building trust with business owners. We earn it through a thoughtful, owner-first approach: understanding the market and their operations, testing strategic fit with our client’s thesis, and managing a well-run process. With proprietary research tools and our multilingual team, we are establishing Aquisor as the leading European buy-side partner our clients can rely on.”

Dirk-Jan Vorgers, CEO, added: “Unlike traditional M&A sourcing firms, Aquisor operates as an extension of its clients’ M&A capabilities, enabling them to focus on what creates most value for them and remaining engaged throughout the entire process..”

Media Enquiries: 
Please contact: [email protected]

About Aquisor
Aquisor is a European M&A buy-side advisory firm focused on pre-deal market mapping and buy-side deal origination for private equity firms. Combining technology-enabled research, multilingual direct outreach, and deep transaction experience, Aquisor delivers high-quality acquisition opportunities and accelerates portfolio growth through platform and add-on acquisitions.

For more information, visit: Aquisor.

Photo – https://mma.prnewswire.com/media/2858390/Aquisor_Logo.jpg

SOURCE Aquisor

LAS VEGAS, Jan. 13, 2026 — BookAI, the pioneer in cross-language Knowledge Computing, announced today the official opening of its Seed Round financing via SAFE notes. The announcement comes immediately after a breakthrough showcase at CES 2026, where BookAI validated its B2B2C model through strategic integrations with AIoT hardware, moving beyond concepts to commercial scalability.

From “Concept” to “Contract”: The Commercial Moat

Unlike many early-stage GenAI startups, BookAI demonstrated market-ready infrastructure capable of handling complex copyright compliance—a critical demand from global IP holders.

“We proved at CES that BookAI is not just a tool, but the ‘Intel Inside’ for the global knowledge economy,” said Kun-Lin Hsieh, Founder and CEO of BookAI. “By embedding our Nabu and Miva engines into third-party devices—like our new partnership with Korean smart lamp maker CN Inc.—we have unlocked a scalable path to transform static content into IntelliBooks and monetize them across borders instantly.”

Dual-Engine Growth Validation:

• The Hardware Engine (CES 2026): Confirmed B2B2C traction. BookAI’s technology successfully powered the DAL:BIT smart lamp, allowing English speakers to interact with Traditional Chinese content in real-time. This “Knowledge-as-a-Service” model attracted immediate inquiries from Japanese venture capital (focused on IP expansion) and Silicon Valley investors (focused on scalable AI infra).
• The Content Engine (Frankfurt Book Fair): Confirmed B2B demand. The Nabu platform was adopted by over 230 publishers from 15 countries, with 62% of traction coming from Western markets, proving a solved pain point in the $600B copyright trading market.

Investment Opportunity: The Seed Round

To capitalize on this global momentum, BookAI has initiated its Seed Round. The raise is structured via SAFE (Simple Agreement for Future Equity) to efficiently onboard strategic partners who align with BookAI’s vision of a borderless knowledge ecosystem.

About BookAI

BookAI is an AI Knowledge Computing Platform transforming how the world accesses information. Backed by Taiwan Tech Arena (TTA), BookAI connects global publishers with AIoT devices, turning static text into IntelliBooks—liquid, interactive, and tradable assets.

Media & Investor Contact: BookAI PR Team Email: [email protected], LinkedIn: https://www.linkedin.com/company/bookai2024

SOURCE BookAI

SHENZHEN, China, Jan. 12, 2026 — X Square Robot, a pioneer in general purpose embodied AI, announced on January 12 the completion of its Series A++ funding round, raising about US$140 million (RMB 1 billion). The funding attracted world-class investors, including ByteDance and HongShan, along with several other strategic Chinese partners.

With leading tech companies such as Alibaba Group and Meituan already backing it from previous rounds, X Square Robot has demonstrated compelling model capabilities and product potential that continue to attract investor confidence.

“We’re honored to have the strong endorsement of our world-class strategic investors,” said WANG Qian, founder and CEO of X Square Robot. “At X Square, we believe the key to enabling robots to truly master real-world tasks lies in the ‘robot brain’—a foundation model for the physical world that parallels virtual LLMs to shatter generalization bottlenecks. This investment underscores shared confidence in our role as a catalyst for technological progress and will accelerate our expansion into high-value applications.”

WALL-A: Integrating VLA with World Models for Continuous Real-World Evolution

Founded in December 2023, X Square Robot is a trailblazer in developing general-purpose end-to-end embodied AI foundation models in China. The company’s in-house developed VLA model, WALL-A, pioneered a system paradigm that deeply integrates VLA with World Models, ranking among the world’s most advanced systems. By using World Models to predict actions and causal inference to understand feedback, the model significantly enhances the zero-shot generalization capabilities of robots performing mobile manipulation tasks in unstructured environments.

Simultaneously, large-scale real-robot reinforcement learning (RL) allows the foundation model to learn through physical interaction. This data-driven approach enables the robot to autonomously refine its skills and perform complex tasks in real-world environments.

Alongside the development of WALL‑A, X  Square Robot introduced WALL‑OSS in September 2025, an open‑source version of its model family designed to democratize embodied intelligence and accelerate community‑driven innovation.

“The next phase of competition in embodied intelligence is essentially a battle of foundation models built on data closed-loops and their capacity for model evolution,” noted Mr. Wang.

To win this race, X Square Robot is also adhering to a closed-loop iteration of hardware, data, and models. As the first company in China to scale up real-world data resources, it has developed advanced data capture tools—including teleoperation, exoskeletons, and Universal Manipulation Interface (UMI). The company has also established a model-driven data pipeline that generates high-quality data at scale. By using the foundation model to provide feedback on hardware design and data processing, X Square Robot is improving acquisition efficiency and model performance, creating a self-reinforcing “flywheel”.

A First in Robotics: Fully Autonomous Food Delivery Using Foundation Models

This end-to-end adaptability is proof that embodied AI has moved into practical, real-world deployment. A landmark breakthrough was recently demonstrated in autonomous food delivery, powered by Wall-A, where the Quanta X1, X Square Robot’s wheeled bimanual robot, successfully navigated indoor and outdoor tasks to complete a delivery in an open environment.

During the mission, Quanta X1 handled challenges such as strong winds, deformed packaging, and visual occlusions. Much like a human, the robot used the model’s causal inference to “fill in the blanks” when objects were partially hidden. When encountering operational stalls or friction, the robot autonomously self-corrects and completes the task loop without any human intervention.

This capacity is also demonstrated in complex logistics; facing piles of parcels, the robot utilizes zero-shot generalization to identify irregular items. Notably, the model’s evolution has unlocked the potential of high DoF (degree of freedom) dexterous hands, mastering human-like skills from tool use to precise card dealing—successfully conquering the “last centimeter” of precision manipulation.

From Full-Stack R&D to Multi-Scenario Deployment

Driven by model and data requirements, X Square Robot has deeply defined its hardware architecture, releasing two high-performance robots: Quanta X1 and the Quanta X2, a wheeled humanoid robot. Meanwhile, X Square Robot also uses in-house developed core components—including robotic arms, joint modules, and controllers—establishing a solid foundation for mass production and commercial scale.

“X Square Robot continues to iterate across our three core pillars: models, data pipelines, and hardware,” said Wang. “By leveraging our technical depth and full-stack R&D, we consistently push the boundaries of robot performance.”

Today, X Square Robot’s solutions are driving “a new era where embodied intelligence powers every layer of productivity.” Its technologies are increasingly deployed across key industry verticals—from advanced manufacturing and autonomous logistics to senior healthcare services.

Email: [email protected] 

SOURCE X Square Robot

BELFAST, Northern Ireland  , Jan. 12, 2026 — PulseAI, a rapidly emerging leader in AI-enabled cardiac diagnostics, today announced the closing of its seed funding round, led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute. The investment will enable PulseAI to scale deployment of its AI-ECG technology and advance its pathway through US FDA 510(k) clearance.

Over 300 million electrocardiograms (ECGs) are performed annually worldwide. However, despite the critical importance of the ECG as a frontline diagnostic tool, its interpretation remains highly dependent on specialist training and manual analysis. This often leads to delays, diagnostic variability, and missed opportunities for early intervention. PulseAI’s AI-ECG platform is designed to address this challenge directly by delivering high-performance clinical decision support in both primary and acute care settings.

As part of the round, Dr. Justin Mortara, an experienced innovator in ECG technologies and former CEO of Mortara Instruments, will join PulseAI as Chair of the Board, strengthening the company’s strategic alignment with global leaders in cardiac monitoring, diagnostics, and hospital systems.

PulseAI’s technology, trained on large-scale ECG datasets and validated in partnership with some of the world’s leading institutions across Europe and the United States, promises to bring the power of AI to one of the most widely used diagnostic tests.

The new investment will accelerate:

• Regulatory advancement, including FDA 510(k), further clinical validation across diverse populations and care settings
• Productisation for enterprise and OEM integration
• Expansion of partnerships with device manufacturers and hospital networks

“This investment marks a pivotal moment for PulseAI as we move into full clinical and regulatory execution,” said Dr Alan Kennedy, Founder and CEO of PulseAI. “Our goal is to deliver advanced ECG technology that can expedite and improve the accuracy of cardiac diagnostics, reducing variability and expanding access to high-quality diagnostics in all areas of healthcare.”

“PulseAI sits at the intersection of clinical rigour, scalable technology, and real market need,” said Justin Mortara, incoming Chair of the Board. “The company is building a platform with the potential to elevate ECG interpretation across the entire care continuum, pairing its AI with traditional medical devices as well as a growing array of consumer wearables. I’m excited to support the team as they move through regulatory milestones to broader industry adoption”

SOURCE PulseAI

NEW YORK, Jan. 12, 2026 — Natixis Corporate & Investment Banking (Natixis CIB) is proud to announce its role as Joint Bookrunner and Joint Lead Arranger in a landmark $281 million project financing for Ruta del Este, concessionaire company formed by ISA Vías (previously Intervial Chile S.A.) to develop the project. This project marks the first concession awarded in Panama under the Public-Private Partnership (PPP) Law of 2019.

The financing will facilitate the execution of the Panamericana del Este road project, a critical infrastructure project that involves the rehabilitation and repaving of an approximately 246-kilometer corridor linking the eastern outskirts of Panama City to the Darien province near the Colombian border. This initiative aligns with Natixis CIB’s commitment to social transportation goals and reinforces its expertise and leadership in the region and sector.

“We are honored to support ISA, ISA Vías, and the Ruta del Este project as it represents a significant milestone as the first-ever PPP concession in Panama,” said Aitor Alava, Head of Infrastructure & Energy Finance Latin America at Natixis CIB. “At Natixis CIB, we are dedicated to partnering with our clients in their efforts to expand into new markets, showcasing our underwriting capabilities in this pioneering financing. The Panamericana del Este, part of Panama’s most vital highway, serves as the primary road link between Panama City and the Guna Yala communities along the coast, as well as the Darien region bordering Colombia. This project is poised to benefit agricultural producers by enhancing their access to demand centers, creating approximately 1,500 direct jobs during construction, and significantly reducing travel time by about 1.5 hours from end to end of the road.”

ISA Vías, a subsidiary of ISA, is recognized as one of the largest operators of road concessions in Latin America, managing over 1,200 kilometers of road infrastructure.

Andres Contreras, Chief Executive Officer (CEO) of ISA Vías, stated, “This operation not only highlights the bank’s confidence in Panama but also showcases ISA Vías´ robust business model, which continues to drive our goal of becoming a leader in road infrastructure across Latin America.”

About Natixis Corporate & Investment Banking
Natixis Corporate & Investment Banking is a leading global financial institution that provides advisory, investment banking, financing, corporate banking and capital markets services to corporations, financial institutions, financial sponsors and sovereign and supranational organizations worldwide.

Our teams of experts in about 30 countries advise clients on their strategic development, helping them to grow and transform their businesses, and maximize their positive impact. Natixis CIB is committed to aligning its financing portfolio with a carbon neutrality path by 2050 while helping its clients reduce the environmental impact of their business.

As part of Groupe BPCE, the second largest banking group in France through the Banque Populaire and Caisse d’Epargne retail networks, Natixis CIB benefits from the Group’s financial strength and solid financial ratings (Standard & Poor’s: A+, Moody’s: A1, Fitch: A+, R&I: A+).

Press contact:
Tara Flanagan, Prosek Partners
Tel: +1 646 818 9022
[email protected]

cib.natixis.com 
https://www.linkedin.com/company/natixis-corporate-investment-banking/
https://www.youtube.com/user/natixisvideos
https://podcast.ausha.co/green-momentum

Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.

SOURCE Natixis

DENVER, Jan. 12, 2026 — Neuramint, the leading AI agent platform empowering developers to build and manage autonomous Web3 workflows, today announced the successful completion of its $5 million seed funding round. The round attracted participation from leading Web3 and AI-focused investment firms, including Maelstrom, Borderless Capital, Selini Capital, Symbolic Capital, Lattice Fund, and Node Capital.

Neuramint enables developers to create intelligent workflows that interact with DeFi protocols, NFT marketplaces, and blockchain networks—all without writing complex smart contract integrations. Through a visual drag-and-drop interface, developers can build, simulate, and deploy autonomous AI agents that coordinate tasks across multiple chains with precision and reliability.

Key differentiators of the Neuramint platform include a visual workflow builder for drag-and-drop agent creation, native multi-chain support across Ethereum, Solana, HyperEVM, and beyond, a production-grade simulation sandbox for safe testing on forked mainnets, gas optimization through intelligent transaction batching, and an agent marketplace for sharing and monetizing workflows.

This seed funding will accelerate platform development, expand Web3-native SDK integrations, and support the upcoming public launch of Neuramint Beta. Proceeds will also drive further integration with major DeFi protocols and blockchain networks, enabling DeFi automation, NFT operations, cross-chain bridging, and DAO governance at scale.

About Neuramint

Neuramint, a Web3 AI company, is at the forefront of the agentic AI revolution, delivering a development platform that empowers developers to automate and manage complex blockchain operations through autonomous AI agents. By combining cutting-edge AI with the flexibility of blockchain, Neuramint is redefining how developers build autonomous agents that interact with decentralized financial ecosystems.

Contact:
Daniel Chan
[email protected]
https://www.neuramint.xyz/

SOURCE NEURAMINT LIMITED

$1 Million NJIEF Investment Matches Edge Medical Ventures Funding to Expand US Commercialization

JERSEY CITY, N.J. and OR YEHUDA, Israel, Jan. 12, 2026 — Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ airway clearance system, today announced it has secured additional funding through a $1M investment from the New Jersey Innovation Evergreen Fund (NJIEF). Matching an Edge Medical Ventures investment, the funding will be used to accelerate U.S. commercial operations, support continued clinical research and product development, and expand patient access to LibAirty™ through respiratory clinics, hospitals, and homecare networks nationwide.

LibAirty™ is the first FDA-cleared airway clearance system providing guided breathing synchronized with targeted chest compressions to help patients clear their lungs effectively and comfortably through a short daily treatment at home. Regular airway clearance is essential for people living with conditions such as chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis to prevent exacerbations, reduce hospitalizations, and improve quality of life. In clinical studies, the system has demonstrated superior sputum clearance and improved user comfort compared to conventional airway clearance devices.

“Synchrony’s vision is to fundamentally change how chronic lung disease is treated at home,” said Anat Shani, CEO of Synchrony Medical. “With the backing of strong partners like Edge Medical and the NJIEF, we have established our U.S. headquarters in New Jersey, home to one of the most dynamic health innovation ecosystems in the country. This additional funding accelerates our ability to scale U.S. commercial activity and expand patient access to LibAirty™ nationwide, while continuing to innovate.”

NJIEF is a public-private partnership under the New Jersey Economic Development Authority (NJEDA), designed to attract, anchor, and scale high-potential companies building and commercializing innovative technologies in New Jersey. The new funding matches an investment by NJIEF Qualified Venture Fund partner Edge Medical Ventures, a medtech venture fund and studio that develops and invests in breakthrough medical technologies with strong clinical validation and global market potential.

“Synchrony’s LibAirty system combines both strong clinical validation and real-world usability, serving as a successful proof-of-concept for our co-investment model with NJEDA,” said Shai Policker, Managing Partner at Edge Medical Ventures. “We are already seeing clear signs of commercial traction and believe Synchrony is well positioned to lead the airway clearance market.”

About Synchrony Medical

Synchrony Medical is a commercial-stage respiratory care technology company developing advanced at-home airway clearance solutions. The company’s FDA-cleared LibAirty™ Airway Clearance system was developed in collaboration with leading pulmonologists at the Sheba Medical Center, inspired by proven airway clearance techniques. LibAirty transforms respiratory therapy into an easy-to-manage daily routine that patients can perform independently at home, setting a new standard of care for people living with chronic lung disease. Founded at the MEDX Xelerator venture studio supported by the Israeli Innovation Authority, Synchrony Medical is headquartered in Jersey City, New Jersey, with additional operations in Or Yehuda, Israel. For more information, visit https://libairty.health/.

Media Contact:

Aviva Sapir
Number 10 Strategies
[email protected]

SOURCE Synchrony Medical

• Mit diesem Durchbruch wird eine seit langem bestehende Herausforderung in der Genmedizin in Angriff genommen, um eine neue Generation von heilenden Zell- und Gentherapien zu entwickeln.
• Entwickelt in Zusammenarbeit mit NVIDIA durch das Training der größten evolutionären KI-Modelle auf einem neuen, weltweit erhobenen Datensatz, beschleunigt durch NVIDIA BioNeMo.
• Dasselbe vielseitige Modell half auch bei der Entwicklung neuartiger antimikrobieller Peptidmoleküle mit einer im Labor bestätigten Erfolgsquote von 97 %, darunter Kandidaten, die sich als hochwirksam gegen multiresistente „Superbugs” erwiesen.
• Basecamp Research gewinnt außerdem NVentures als Investor vor der Series C-Finanzierungsrunde nach intensiver technischer Zusammenarbeit bei EDEN-Modellen.

LONDON und CAMBRIDGE, Massachusetts, — Basecamp Research, ein Pionierlabor für KI, das sich die Evolution zunutze macht, um neue Medikamente zu entwickeln, gab heute die ersten KI-Modelle bekannt, die in der Lage sind, programmierbare Gene einzufügen, und damit eine neue Möglichkeit bieten, fehlerhafte Gene zu ersetzen und Zellen für therapeutische Zwecke umzuprogrammieren. Diese in Zusammenarbeit mit NVIDIA ausgebildeten Modelle treiben die Entwicklung einer neuen Generation von Behandlungen für Krebs und Erbkrankheiten voran. Gleichzeitig sicherte sich Basecamp Research nach mehrjähriger enger technischer Zusammenarbeit eine Investition von NVentures (NVIDIAs Risikokapitalarm) in seiner Pre-Series-C-Runde, die dem Unternehmen helfen wird, seine Forschungs- und Entwicklungsbemühungen zu beschleunigen.

„Wir glauben, dass wir am Anfang einer großen Erweiterung der Möglichkeiten für Patienten mit Krebs und genetischen Erkrankungen stehen”, sagte John Finn, Chief Scientific Officer bei Basecamp Research. „Durch den Einsatz von KI bei der Entwicklung des therapeutischen Enzyms hoffen wir, die Entwicklung von Heilmitteln für Tausende von unbehandelbaren Krankheiten zu beschleunigen und damit möglicherweise das Leben von Millionen von Menschen zu verändern.”

Programmierbare Gen-Insertion

Die programmierbare Gen-Insertion – die Platzierung großer therapeutischer DNA-Sequenzen an präzisen Stellen im menschlichen Genom – ist seit Jahrzehnten ein zentrales Ziel der Genmedizin. Bestehende CRISPR-basierte Ansätze können nur kleine Änderungen vornehmen und müssen dazu die DNA beschädigen, was ihre Einsatzmöglichkeiten einschränkt. Basecamp Research hat als erstes Unternehmen gezeigt, dass KI Enzyme entwerfen kann, die in der Lage sind, große Mengen an Genen an bestimmten Stellen in das menschliche Genom einzufügen, und damit einen lange gesuchten Weg zu programmierbaren Therapien eröffnet.

Die Plattform AI-Programmable Gene Insertion (aiPGI^™) von Basecamp Research wird von EDEN angetrieben, einer neuen Familie evolutionärer KI-Modelle, die mit NVIDIA entwickelt und auf BaseData^™ trainiert wurden, dem proprietären und seiner Art nach größten Genomik-Datensatz des Unternehmens. Die Modelle lernen die Sprache der DNA und die Muster der Evolution, so dass die Algorithmen neue, programmierbare Therapien für Krebs und genetische Krankheiten entwickeln können.

In den Laborergebnissen, die heute in einer von NVIDIA, Microsoft und führenden Wissenschaftlern gemeinsam verfassten Publikation [Link] veröffentlicht wurden, haben die EDEN-Modelle mehrere aktive Insertionsproteine für 100 % der getesteten krankheitsrelevanten Zielstellen im menschlichen Genom entworfen, wobei nur die genomische Zielstelle als Eingabeaufforderung erforderlich war. Dies markiert einen signifikanten Fortschritt in der Leistungsfähigkeit von KI-Modellen.

Basecamp Research hat bereits die Insertion an über 10.000 krankheitsrelevanten Stellen im menschlichen Genom nachgewiesen, einschließlich der therapeutisch relevanten Integration krebsbekämpfender DNA in primäre menschliche T-Zellen an neuartigen Safe-Harbour-Stellen. Daraus entstanden CAR-T-Zellen, die Krebszellen stark abtöten und in Labortests über 90 % der Tumorzellen vernichten.

KI-entwickelte Moleküle zur Bekämpfung von „Superbugs”

Bei einer anderen wichtigen Pionieraufgabe im Bereich des therapeutischen Designs, die auf die weltweite Krise der Arzneimittelresistenz abzielt, bewies dasselbe Modell seine Vielseitigkeit, indem es eine gezielte Bibliothek neuartiger antimikrobieller Peptide (AMPs) – kleine Proteine mit dem Potenzial, schädliche Bakterien abzutöten – entwarf, wobei 97 % der Kandidaten in Labortests eine bestätigte Aktivität aufwiesen. In Zusammenarbeit mit Wissenschaftlern der University of Pennsylvania unter der Leitung von Prof. César de la Fuente zeigten die am besten abschneidenden AMPs eine hohe Wirksamkeit gegen kritische, multiresistente Krankheitserreger und bieten damit ein leistungsstarkes neues Instrument im Kampf gegen gefährliche „Superbugs”.

Durchbruch dank einzigartiger Daten und bahnbrechender KI-Modelle

Die EDEN-Modelle, die aiPGI^™ antreiben, wurden auf über 10 Billionen Token evolutionärer DNA von mehr als einer Million neu entdeckter Arten trainiert. Diese Daten wurden über einen Zeitraum von fünf Jahren an über 150 Standorten in 28 Ländern und auf fünf Kontinenten im Rahmen einer neuartigen, vom Unternehmen entwickelten Datenerhebungsstrategie gesammelt und im Juni 2025 veröffentlicht.

Das größte EDEN-Modell wurde mit einer Rechenleistung von 1,95 x 10²⁴ FLOPS auf einem Cluster von 1.008 NVIDIA Hopper GPUs trainiert und mit Bibliotheken von NVIDIA BioNeMo beschleunigt. Damit ist es von der Größenordnung her mit Modellen der Klasse GPT-4 vergleichbar und zählt zu den rechenintensivsten biologischen Modellen, die jemals gemeldet wurden.

Therapeutische Wirkstoffe in der Entwicklung

Diese Fähigkeiten untermauern die entstehende Pipeline von Zell- und Gentherapien von Basecamp Research und ebnen den Weg für Behandlungen, die präziser, besser vorhersagbar und individueller sind als die heute verfügbaren. Das Ziel des Unternehmens ist es, potenziell heilende Therapien für eine Reihe von Krebs- und genetischen Erkrankungen zu entwickeln, gestützt auf kontinuierliche Verbesserungen von BaseData^™, den EDEN-Modellen und aiPGI^™.

Informationen zu Basecamp Research
Basecamp Research widmet sich der Lösung zentraler Herausforderungen in den Biowissenschaften durch die Erforschung von Beyond Known Biology^™. Das Unternehmen erstellt bahnbrechende KI-Modelle auf der Grundlage von BaseData, dem weltweit größten ethisch fundierten und global repräsentativen biologischen Datensatz. Basecamp Research sammelt und kuratiert seine eigenen biologischen Daten durch Partnerschaften mit mehr als 152 Organisationen in 28 Ländern und verschafft seiner KI damit Zugang zu einer genetischen Vielfalt, die für Modelle, die auf öffentlichen Datenbankquellen trainiert werden, nicht existiert. Dadurch kann Basecamp Research neue Proteinsequenzen und biologische Systeme entwerfen, die die therapeutische Forschung und Entwicklung beschleunigen können.

Basecamp Research arbeitet mit biopharmazeutischen Unternehmen und akademischen Einrichtungen auf der ganzen Welt zusammen. Die Arbeit von Basecamp Research wurde mit Auszeichnungen gewürdigt, darunter Fast Company’s Top 10 Most Innovative Companies in Biotech und die von FT unterstützte Sifted AI100-Liste der führenden KI-Startups in Europa. Weitere Informationen finden Sie unter basecamp-research.com.

BaseData^™, Beyond Known Biology^™, EDEN-GLM^™ und aiPGI^™ sind Markennamen und Technologien von Basecamp Research.